Independent
Tenure on this board
9.2 yrs
Meeting calendar
MEDP · Annual meeting · Friday, May 15, 2026
Medpace Holdings Inc
5 nominees · 7 ballot items.
Election of five directors; ratification of Deloitte & Touche LLP as auditor; advisory Say-on-Pay vote; advisory Say-on-Frequency vote (one year recommended); amendment to Certificate of Incorporation to remove supermajority voting requirements; amendment to Certificate of Incorporation to allow stockholders to call special meetings (removing current limitation); consideration of a stockholder proposal to allow shareholders holding 10% to call special meetings.
Market cap
$15.4B
1Y TSR
+40.9%
Board grade
A-
Record date
Mar 19, 2026
Filing
DEF 14A
Meeting concluded · May 15, 2026
Follow how the vote landed and what changed on Medpace Holdings Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot7
- 1
Election of Directors
ManagementBoard: FORElect five director nominees (three Class I: Brian T. Carley, Femida H. Gwadry-Sridhar, Robert O. Kraft; two Class III: August J. Troendle, Dani S. Zander) to serve until 2027 Annual Meeting.
- 2
Ratification of Appointment of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
- 3
Advisory Vote on the Compensation of Our Named Executive Officers (Say-on-Pay
ManagementBoard: FORNon-binding advisory vote to approve the compensation of named executive officers as disclosed in the proxy statement.
- 4
Advisory Vote on the Frequency of Future Advisory Votes on the Compensation of Our Named Executive Officers (Say-on-Frequency
ManagementBoard: FORNon-binding advisory vote to select whether advisory votes on executive compensation should occur every one, two, or three years (Board recommends one year).
- 5
Amendment of Certificate of Incorporation to Remove Supermajority Voting Requirements
ManagementBoard: FORAmend Restated Certificate of Incorporation to eliminate 66-2/3% supermajority voting thresholds and opt into DGCL Section 242(d), adopting majority voting standards for most amendments and director removal.
- 6
Amendment of Certificate of Incorporation to Remove the Limitation on Stockholders Calling Special Meetings of Stockholders
ManagementBoard: FORAmend Article ELEVENTH of Restated Certificate to allow special meetings to be called as authorized in Bylaws, and adopt Bylaws granting stockholders holding 25% continuous ownership for one year the right to request special meetings with procedural requirements.
- 7
Stockholder Proposal — Give Shareholders an Ability to Call for a Special Shareholder Meeting
Shareholder — Unnamed stockholder (name/address to be provided upon requestBoard: AGAINSTStockholder proposal requests that holders of combined 10% of outstanding common stock be able to call a special shareholder meeting without ownership time requirements; includes supporting statement alleging governance concerns and urging vote.
Director elections
Nominees on the ballot5
Independent
Tenure on this board
3.5 yrs
Independent
Tenure on this board
10.0 yrs
Not independent
Tenure on this board
34.0 yrs
Independent
Tenure on this board
2.0 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | BlackRock, Inc. | 5.5% | 1,565,180 | $752M |
| 2 | AQR CAPITAL MANAGEMENT LLC | 4.7% | 1,336,210 | $625M |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 3.9% | 1,121,689 | $539M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 3.5% | 1,011,071 | $486M |
| 5 | WASATCH ADVISORS LP | 2.7% | 773,931 | $372M |
| 6 | STATE STREET CORP | 2.4% | 682,229 | $328M |
| 7 | BlackRock, Inc. | 2.3% | 664,876 | $319M |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 2.3% | 662,719 | $318M |
| 9 | RENAISSANCE TECHNOLOGIES LLC | 1.8% | 504,668 | $242M |
| 10 | Invesco Ltd. | 1.7% | 497,087 | $239M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Medpace Holdings Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Jazz Pharmaceuticals PLCJAZZ
Annual meeting·Jul 23, 2026·$15.2B
Apogee Therapeutics IncAPGE
Special meeting·Aug 11, 2026·$10.1B
Steris PLCSTE
Annual meeting·Jul 31, 2026·$21.6B
Amneal Pharmaceuticals IncAMRX
Special meeting·Jul 31, 2026·$5.8B
Doximity IncDOCS
Annual meeting·Aug 27, 2026·$4.1B
Haemonetics CorpHAE
Annual meeting·Jul 24, 2026·$3.6B
Reference
Frequently asked questions
- When is the Medpace Holdings Inc 2026 annual meeting?
- Medpace Holdings Inc (MEDP) holds its 2026 annual shareholder meeting on Friday, May 15, 2026.
- What is the record date for the Medpace Holdings Inc 2026 meeting?
- The record date for the Medpace Holdings Inc 2026 meeting is Thursday, March 19, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Medpace Holdings Inc's 2026 meeting?
- The board is presenting 5 director nominees at the Medpace Holdings Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Medpace Holdings Inc 2026 meeting?
- Shareholders will vote on 7 proposals at the Medpace Holdings Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.